GB201103762D0 - Means and methods for the treatment of neurodegenerative disorders - Google Patents
Means and methods for the treatment of neurodegenerative disordersInfo
- Publication number
- GB201103762D0 GB201103762D0 GB201103762A GB201103762A GB201103762D0 GB 201103762 D0 GB201103762 D0 GB 201103762D0 GB 201103762 A GB201103762 A GB 201103762A GB 201103762 A GB201103762 A GB 201103762A GB 201103762 D0 GB201103762 D0 GB 201103762D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- methods
- disease
- directed against
- neurodegenerative disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
The present invention has found that inhibitors reducing the glycolytic flux can be used for treatment of neurodegenerative diseases such as Alzheimer's disease, Parkonson's disease and amyotrophic lateral sclerosis. In particular the invention provides constructs comprising siRNAs directed against PHD1 for the treatment of ALS and siRNA's directed against PFKFB3 for the treatment of neurodegenerative diseases. The invention also provides the use of a therapeutically effective amount of aza chalcones or a pharmaceutically acceptable salt thereof for the treatment of neurological diseases.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201103762A GB201103762D0 (en) | 2011-03-07 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
PCT/EP2012/053646 WO2012119949A1 (en) | 2011-03-04 | 2012-03-02 | Means and methods for the treatment of neurodegenerative disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201103762A GB201103762D0 (en) | 2011-03-07 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201103762D0 true GB201103762D0 (en) | 2011-04-20 |
Family
ID=43923244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201103762A Ceased GB201103762D0 (en) | 2011-03-04 | 2011-03-07 | Means and methods for the treatment of neurodegenerative disorders |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201103762D0 (en) |
WO (1) | WO2012119949A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015187934A1 (en) * | 2014-06-06 | 2015-12-10 | Cureveda, Llc | Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use |
CN113396145A (en) * | 2018-10-15 | 2021-09-14 | 盖罗发现有限责任公司 | PFKFB3 inhibitors and uses thereof |
CA3218941A1 (en) * | 2021-05-16 | 2022-11-24 | Slavica TUDZAROVA-TRAJKOVSKA | Methods and compositions for treating neurological conditions |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
WO2005014815A1 (en) * | 2003-08-08 | 2005-02-17 | President And Fellows Of Harvard College | siRNA BASED METHODS FOR TREATING ALZHEIMER’S DISEASE |
JP2010531304A (en) | 2007-06-18 | 2010-09-24 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド | PFKFB3 inhibitor family with antineoplastic activity |
-
2011
- 2011-03-07 GB GB201103762A patent/GB201103762D0/en not_active Ceased
-
2012
- 2012-03-02 WO PCT/EP2012/053646 patent/WO2012119949A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012119949A1 (en) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
MY161656A (en) | Therapeutic use of diaminophenothiazines | |
EA201891833A1 (en) | COMBINATION FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS OR RELATED DISEASES | |
TN2013000414A1 (en) | 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma | |
MX2013011908A (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors. | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
MX348941B (en) | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer. | |
MX2009010407A (en) | Fluorinated derivatives of deferiprone. | |
IN2015DN00450A (en) | ||
PH12015500664A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
MX349224B (en) | Pharmaceutical composition for use in the treatment of a neurodegenerative disease. | |
PH12014501140A1 (en) | Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. | |
GB201103762D0 (en) | Means and methods for the treatment of neurodegenerative disorders | |
MX340536B (en) | Egfr targeted therapy. | |
PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |